Subject: An observational survey study to analyze the management of Interstitial lung diseases
Interstitial lung disease (ILD) is an inflammatory condition of the interstitium of lungs.1 It comprises of large group of > 200 parenchymal pulmonary disorders, of which the majority are classified as rare. The pathogenesis of ILD involves a series of inflammation and fibrosis that extends beyond disrupting the interstitial bed to changing the parenchyma (alveoli, alveolar ducts, and bronchioles)2
Interstitial lung disease (ILD) refers to a heterogeneous group of over 200 disorders with varied clinical presentation and prognoses. Many of the subsets of the disease are of unknown etiology. Regardless, they all ultimately share the same manner of development. The morphological changes seen histologically result from a sequence of inflammation within the parenchyma, which is the portion of the lung involved in gas exchange (the alveoli, the alveolar ducts, and the bronchioles). This compartment is the habitat to various proteins and pro-fibrotic elements. These proteins, after repeated cycles of activation, give rise to accumulation of connective tissue.3
For those interstitial lung disorders with known causes, avoidance of irritant is essential. General supportive measures will include smoking cessation, pulmonary rehabilitation which can help improve functionality, and good pulmonary hygiene. Supplemental oxygen is necessary for those who demonstrate hypoxemia (SaO2 less than 88). With progressive disease despite the elimination of offending agent, corticosteroids are desirable. Patients with bronchiolitis obliterans organizing pneumonia (BOOP) or hypersensitivity pneumonitis (HP) have rapid, dramatic improvement with corticosteroids. For cases that do not respond to corticosteroids, immunosuppressant therapy is an investigational therapy.
The mainstay therapy for treatment of idiopathic interstitial pneumonia is corticosteroids and immunosuppressive therapies to intercept the inflammatory process within the lungs.4 Right now, Nintedanib and pirfenidone are immunosuppressant drugs that have been approved but only in the treatment of idiopathic pulmonary fibrosis.5 Some studies have provided indirect evidence that early therapy within the course of the disease might correlate with therapeutic responsiveness because the lung architecture has not suffered significant derangement. Once fibrosis initiates, there has not been any treatment to reverse that process, but Nintedanib can slow disease progression.6 Transplant is the sole treatment modality that can reinstate physiological function in patients.
There are multiple modalities of therapy including surgical and medical treatments
A variety of drugs including inhalation formulations of corticosteroids, anti-fibreoptics, immunosuppressants. are used for medical management.
Hence, we designed the current study to analyze the management of Interstitial lung diseases
If you agree to participate, you will need to fill data collection forms (which we call DCF).
We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.
|
}}){kind=logo}